Année
2023
Auteurs
PUYOU DE POUVOURVILLE Gérard, ROSSIGNOL Patrick, BOUSSAHOUA Meriem, CHEVALIER Julie, GABB Peter D., POULNAIS Roch, VERBOUX Dorian, RAO Naveen, SÖRSTADIUS Elisabeth, GARCIA SANCHEZ Juan Jose
Abstract
Gliflozins have historically been indicated for type 2 diabetes in France. However, their efficacy has recently been demonstrated in heart failure and chronic kidney disease (CKD), with positive recommendations by Haute Autorité de Santé for gliflozin therapies in these indications. The study objective was to investigate the 5-year budget impact associated with the introduction of gliflozins in addition to standard therapy in people with CKD and elevated albuminuria, regardless of diabetes status, from the perspective of the French healthcare system.
PUYOU DE POUVOURVILLE, G., ROSSIGNOL, P., BOUSSAHOUA, M., CHEVALIER, J., GABB, P.D., POULNAIS, R. … GARCIA SANCHEZ, J.J. (2023). Budget Impact Analysis of Expanding Gliflozin Coverage in the CKD Population: A French Perspective. Advances in Therapy, 40, pp. 3751-3769.